Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Clinical trial enrollment has long been a bottleneck in drug development
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Subscribe To Our Newsletter & Stay Updated